[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482271":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Brain Metastases",null,"Participants will have at least one untreated brain metastasis \\> 1cm",[13],"Diagnostic Test: CEST-MRF",{"label":15,"type":10,"description":16,"interventionNames":17},"Healthy participants","Participants will have no known cancer diagnosis. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","CEST-MRF","CEST-MRF enables accurate quantification of both proton exchange rates and volume fractions in a fraction of the time required by conventional pulse sequences will be developed and optimized.",[15,9],[25],"chemical exchange saturation transfer magnetic resonance fingerprinting method",[27],{"name":28,"affiliation":5,"role":29},"Ouri Cohen, PhD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","646-608-8259","coheno1@mskcc.org",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},"Nelson Moss, MD","212-639-7075","mossn@mskcc.org",[40],{"facility":41,"status":42,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","RECRUITING","New York","10065","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-74.00597,40.71427,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":33,"phoneExt":10,"email":34},"Ouri Coheb, PhD",{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100482271","developing-a-new-mri-technique-to-understand-changes-in-brain-tumors-after-treatment-100482271",false,"NCT05559853","Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment","Development of a Clinical CEST MR Fingerprinting Method for Treatment Response Assessment in Brain Metastases","Inclusion Criteria:\n\nHealthy volunteers \\[for Study Aim 1 (SA1) and Study Aim 2 (SA2)\\] will be entered into the study if they meet the following criteria:\n\n* Age ≥ 18 years\n* Able to understand and give informed consent\n* No known cancer diagnosis\n\nPatients \\[for Study Aim 1 (SA1)\\] will be entered into the study if they meet the following criteria:\n\n* Age ≥ 18 years\n* Able to understand and give informed consent\n* At least one untreated brain metastasis \\> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)\n\nPatients \\[for Study Aim 3 (SA3)\\] will be entered into the study if they meet the following criteria:\n\n* Age ≥ 18 years\n* Able to understand and give informed consent\n* At least one untreated brain metastasis \\> 1cm (e.g., an enhancing lesion in the brain of a patient with known systemic cancer determined likely to represent metastasis by neuroradiologist)\n* Planned SRS treatment\n\nExclusion Criteria:\n\nHealthy volunteers (SA1 \\& SA2) and patients (SA1 \\& SA3) exclusion criteria:\n\n* Pregnant or breastfeeding women\n* Pre-existing medical conditions, including the likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest\n* Age \\\u003C 18 years",true,"ALL","18 Years",{"count":69,"type":70},119,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).",[74,75,76,77],"Brain Metastases","Brain Metastases, Adult","Metastatic Brain Tumor","Metastatic Brain Cancer",[74,79,80,81,75,82,83,21,84,85,5],"Healthy Volunteers","metastatic brain tumor","metastatic brain cancer","MRI","untreated brain metastasis","chemical exchange saturation transfer magnetic resonance fingerprinting","22-191","2026-03-04",{"date":88,"type":89},"2026-03-06","ACTUAL",{"date":91,"type":89},"2022-09-22",{"date":93,"type":70},"2027-09-22",{"name":5,"class":6},1]